Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Grit Biotechnology’s lead non-gene-engineered TIL product (GT101) is in pivotal Phase 2 trials in China with a planned BLA filing in 2025. Their next-generation genetically engineered TIL product (GT201), based on proprietary expansion and gene-editing platforms to enhance efficacy and persistence of T cells while reducing IL‑2 dependence, has received IND clearance from both Chinese and US regulators. Early clinical data show stable in-vivo expansion and preliminary efficacy with a good safety profile in advanced solid tumor patients
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Forged Grit.